Self-Expanding Evolut Valve non-inferior to Balloon-Expandable SAPIEN Valve in Severe Aortic Stenosis and Small Aortic Annuli
Key Points: The SMART trial is the first randomized non-inferiority trial to test a head-to-head comparison between the Medtronic Evolut valve (Evolut PRO/PRO+/FX) and Edwards SAPIEN valve (SAPIEN 3/3 Ultra)…
A single SC dose of Zilebesiran reduced systolic blood pressure in uncontrolled hypertension: KARDIA-2
Key Points: Zilebesiran is a subcutaneous injectable that targets hepatic angiotensinogen (AGT) synthesis by RNA interference. The KARDIA-1 trial showed that subcutaneous zilebesiran is associated with sustained reduction in systolic…
BE ACTIVE RCT: Financial incentive and gamification strategies borrowed from behavioral economics increased physical activity among adults at elevated ASCVD risk
Key Points: The majority of US adults at elevated risk for ASCVD do not engage in the recommended amount of daily exercise. Behavioral economic strategies to incentivize increased physical activity…
STEP-HFpEF DM TRIAL: Semaglutide improves HF-related symptoms and results in greater weight loss among patients with obesity-related HFpEF and type 2 DM
Key Points: Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has previously been shown to reduce body weight and improve HF-related symptoms among individuals with HFpEF and obesity who did not have…
Remote Acute Assessment Of Patients With High Cardiovascular Risk Post-Acute Coronary Syndrome (TELE-ACS)
Key Points: TELE-ACS evaluates the use of telemedicine strategies to reduce hospital readmission rates in patients with a recent history of acute coronary syndrome There was a 76% reduction in…
An “Inclisiran First” Strategy Shows Greater LDL-C Lowering Compared With Usual Care In Patients With ASCVD: The VICTORION-INITIATE Randomized Trial
Key Points: Most patients with atherosclerotic cardiovascular disease (ASCVD) do not achieve sufficiently reduced low-density lipoprotein cholesterol (LDL-C) levels despite maximum-tolerated lipid-lowering therapy (LLT) to improve cardiovascular outcomes. Twice-yearly inclisiran…
EMPACT-MI: Empagliflozin did not meet primary endpoint but significantly reduced HF hospitalizations
Key Points: Incident heart failure remains common among patients who experience acute myocardial infarction despite recent advances in medical therapy and revascularization strategies. The EMPACT MI trial randomized 6,522 participants…
Self-monitoring and physician-optimized antihypertensive titration post-partum decreases BP during the first 9 months
Key Points: Up to 1 in 10 women experience a hypertensive disorder of pregnancy, which is associated with long-term cardiovascular disease. However there are no established interventions to reduce risk…
Novel RNA interference therapeutic Zilebesiran results in dose-dependent sustained BP reduction
Key Points: Uncontrolled hypertension is a major public health concern, and this condition is often primarily driven by the renin-angiotensin (RAAS) pathway. A new RNA interference therapy, Zilebesiran, was developed…
VERVE-101, a novel DNA-base editing medication, results in dose-dependent reductions in blood PCSK9 and LDL-C
Key Points: Despite the advent of PCSK9 inhibitors, the majority of patients with familial hypercholesterolemia do not meet their LDL-C targets with standard therapies. VERVE-1 is a novel CRISPR base…
A multi-level hypertension program improved hypertension control in Nigeria
Key Points: The global burden of hypertension is high and increasing, with high rates of underdiagnosis and undertreatment. This study implemented a multi-pronged implementation package of HTN treatment within the…
IMPACTS: A multifaceted implementation significantly improved BP control among low-income patients
Key Points This cluster-randomized trial found that a multifaceted implementation strategy to target an SBP <120 among low-income patients cared for at FQHCs lead to a significant reduction in mean…
SPEECH: Novel speech analysis technology may be useful for early recognition of worsening heart failure events
Key Points Novel speech processing technology has the potential to detect heart failure exacerbations before they happen, and may be better than the conventional weight monitoring approach. Additional studies are…
SUPER-LIPID: Non-visit based automated orders sent to central pharmacy increased appropriate statin prescriptions
Key Points In two simultaneous pragmatic trials, an asynchronous, non-visit based, automated order for statins placed to a centralized pharmacy significantly increased both overall statin and appropriate dose statin prescriptions,…
Recaticimab Effective as Add-On Therapy in Non-Familial Hypercholesterolaemia and Mixed Hyperlipidemia: REMAIN-2 Trial
Key Points Recaticimab effectiveness demonstrated dosage-dependent response indicating versatility in treatment options. Sustained reduction in LDL-C levels throughout the 48-week study period as well as favorable outcomes observed in additional…
Dual Cardioversion More Effective than Single in Obese Patients with AF
Key Points: The prevalence of obesity, and AF is increasing substantially and are inextricably linked. Patients with obesity show less response to single-DCCV due to chest wall impedance This trial…
AI -ECG Results in Faster and More Accurate Identification of STEMI
Key Points: The use of an artificial intelligence electrocardiogram (AI-ECG) support tool in the evaluation of patient ECGs was associated with a reduction in the door to coronary angiography time…
Abelacimab, a novel Factor XI/XIa Inhibitor, reduced bleeding vs Rivaroxaban in AF
Key Points: Previous studies have investigated the use of direct oral anticoagulants (DOACs) instead of warfarin for reduction of stroke risk in AF, but the risk of clinically significant bleeding…
Coronary Inflammation on CCTA as Predictor of Cardiac Events: the ORFAN Study
Key Points: Out of all patients who undergo a CCTA, the highest number of cardiac events occurs in patients without obstructive CAD. In patients with non-obstructive CAD on CCTA, the…
ESPIRIT: Intensive blood pressure control lowers MACE vs Standard Treatment
Key Points This randomized trial of 11255 patients in China with established CVD or at least 2 CVD risk factors but without a significantly reduced ejection fraction or advanced kidney…